Graphical abstract

***In silico* screening of minocycline as an Mpro inhibitor and the adjunctive therapy value for the treatment of COVID-19**

Bin Xiao1, Si Wu1, Yaru Han1, Liwen Ren2, Jinhua Wang2, Xiurong Luan1, Guanhua Du2,\*, and Zhanfei She1,\*

*1Laboratory of Clinical Pharmacy, Ordos Central Hospital, Ordos School of Clinical Medicine, Inner Mongolia Medical University, Ordos 017000, China; 2Beijing Key Laboratory of Drug Target Identification and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China*

